A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants

PHASE1RECRUITING

This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose, Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of BX-001N after intravenous administration in approximately 64 healthy participants.

info
Simpliy with AI

Study details:

This study comprises of 2 parts:. * Part 1- Single Ascending Dose (SAD)- This part will enroll approximately 40 participants across 5 cohorts where each participant will receive a single intravenous (IV) bolus dose in healthy participants. On Day 1, participants in each cohort will receive investigational product (IP) (i.

e. , BX-001N or Placebo) as a single IV bolus following a minimum 8-hour fast. * Part 2 -Multiple Ascending Dose (MAD)- This part will enroll approximately 24 participants across 3 cohorts where each participants will receive intravenous (IV) bolus dose for 7 sequential daily.

At the same time each morning from Day 1 to Day 7 (inclusive), participants in each cohort will receive IP (i. e. , BX-001N or Placebo) as a single IV bolus following a minimum 8-hour fast.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • 18 to 50 years of age
  • In good general health at Screening and/or before the first administration of IP
  • BMI > 18.0 and < 32.0 kg/m2 at Screening
  • Nonsmoker and must not have used any tobacco products within 2 months prior to screening
  • Females must not be pregnant or lactating, and females and males must use acceptable, highly effective double contraception during study and follow-up period
  • Person who can provide written informed consent prior to the commencement of all study procedures
  • Exclusion criteria

  • Underlying physical or psychological medical condition to comply with the protocol or complete the study per protocol
  • Genetic disorder with severe and abnormal bilirubin metabolism
  • Blood or plasma donation or significant blood loss prior to the first administration of IP
  • Viral or bacterial infection prior to the first administration of IP
  • Poor venous access
  • Significant scarring or tattoos at the planned site of IP administration
  • History of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents
  • History or active cardiovascular, respiratory, kidney, endocrine, blood, digestive, central nervous, urinary and/or musculoskeletal disease
  • History of malignancy prior to Screening
  • Abnormal ECG findings
  • History or presence of a condition associated with significant immunosuppression
  • History of life-threatening infection
  • Infections requiring parenteral antibiotics
  • Vaccination prior to the first administration of IP
  • Exposure to any significantly immune suppressing drug
  • Abnormal vital signs findings
  • Abnormal laboratory findings
  • Positive results for viral testing at Screening
  • Positive result at Screening and Day -1 for toxicology screening panel
  • History of substance abuse or dependency or history of recreational intravenous (IV) drug use
  • Excess of regular alcohol consumption
  • Use of any IP or investigational medical device within 30 days prior to Screening
  • Unable to adhere to the prohibited therapies
  • Unwilling to adhere to the dietary restrictions
  • Unwilling to refrain from strenuous exercise
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : Yes

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2023-11-17

    Primary completion: 2024-09-30

    Study completion finish: 2024-12-31

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT06097702

    Intervention or treatment

    DRUG: BX-001N Part 1

    DRUG: BX-001N Part 2

    DRUG: Placebo

    Conditions

    • Ischemia-reperfusion Injury

    Find a site

    Closest Location:

    CMAX Clinical Research

    Research sites nearby

    Select from list below to view details:

    • CMAX Clinical Research

      Adelaide, South Australia, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: BX-001N Part 1
    • Part 1 is SAD with 5 cohorts where each participant will receive single IV bolus following a 8hr fast.
    DRUG: BX-001N Part 1
    • Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.
    EXPERIMENTAL: BX-001N Part 2
    • Part 2 is MAD with 3 cohorts where each participant will receive 7 sequential daily IV bolus doses following a 8hr fast.
    DRUG: BX-001N Part 2
    • Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 7 sequential days in one of the three doses based on body weight and followed up for 14 days.
    PLACEBO_COMPARATOR: Placebo
    • Matching doses of placebo
    DRUG: Placebo
    • Participants will receive matching placebo across Part 1 and 2 of the study.

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Number of participants with Treatment emergent Adverse events (TEAEs)TEAE will be collected to assess participants' safety after BX-001N treatmentSAD-Screening to Day 7; MAD- Screening to Day 14
    Number of participants with clinical laboratory abnormalitiesNot SpecifiedSAD-Screening to Day 7; MAD- Screening to Day 14
    Number of participants with changes in the 12-lead electrocardiogram (ECG)Not SpecifiedSAD-Screening to Day 7; MAD- Screening to Day 14
    Number of incidences of injection site reactionsNot SpecifiedSAD-Day 1 to Day 2; MAD- Day 1 to Day 8

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Changes in Cmax (maximum Concentration) of BX-001N with 5 different doses of SAD and 3 different doses of MADSAD's samples of PK are collected at total 12 time points from pre-dose and up to Day 3 after dosing. MAD's samples of PK are collected at total 26 time points from pre-dose and up to Day 8 after dosing.SAD- Day 1 to Day 3; MAD- Day 1 to Day 8
    Changes in Tmax (Time of maximum Concentration) of BX-001N with 5 different doses of SAD and 3 different doses of MADSAD's samples of PK are collected at total 12 time points from pre-dose and up to Day 3 after dosing. MAD's samples of PK are collected at total 26 time points from pre-dose and up to Day 8 after dosingSAD- Day 1 to Day 3; MAD- Day 1 to Day 8
    Changes in AUC (area under curve) of BX-001N with 5 different doses of SAD and 3 different doses of MADSAD's samples of PK are collected at total 12 time points from pre-dose and up to Day 3 after dosing. MAD's samples of PK are collected at total 26 time points from pre-dose and up to Day 8 after dosing.SAD- Day 1 to Day 3; MAD- Day 1 to Day 8
    Change in Immunogenicity- Incidence of Anti-drug antibody (ADA) by polyethylene glycol (PEG)Up to 3 samples will be collected in total and additional samples if positive resultsSAD-Day 1 to Day 7; MAD- Day 1 to Day 14
    Change in Immunogenicity- Titers of Anti-drug antibody (ADA) by polyethylene glycol (PEG)Up to 3 samples will be collected in total and additional samples if positive resultsSAD-Day 1 to Day 7; MAD- Day 1 to Day 14
    Change in Immunogenicity- Duration of Anti-drug antibody (ADA) by polyethylene glycol (PEG)Up to 3 samples will be collected in total and additional samples if positive resultsSAD-Day 1 to Day 7; MAD- Day 1 to Day 14

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants

    Other trails to consider

    Top searched conditions